deutsch
03.04.2007
Tumour M2-PK as a stool marker for colorectal cancer
Comparative analysis in a large sample of unselected older adults vs colorectal cancer patients.
Stool testing based on tumour-derived markers might offer a promising approach for non-invasive colorectal cancer (CRC) screening. The aim of this study was to estimate the potential of a new test for faecal tumour M2-PK to discriminate patients with CRC from a large sample of unselected older adults.
Click here to read the whole article
Click here to read the whole article
A Decade of UK Success for Schebo Biotech
ScheBo® Biotech UK Limited, a leading provider of unique in-vitro diagnostic tests for the healthcare sector, has just celebrated its 10th Anniversary.
more...
more...
A superior alternative for PLT users: Faecal Pancreatic Elastase Test
Pfizer recommends this test in a letter it sent to pharmacists notifying them about the withdrawal of PLT.
more...
more...
Tumour M2-PK as a stool marker for colorectal cancer
Comparative analysis in a large sample of unselected older adults vs colorectal cancer patients.
more...
more...
Coeliac disease and pancreatic exocrine insufficiency
The data have shown that pancreatic insufficiency, demonstrated by low faecal pancreatic elastase-1 levels, is common in adult coeliac disease patients.
more...
more...
Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK
Fecal tumor M2-PK is an appropriately sensitve tool to pre-select those patients requiring colonoscopy for the further diagnostic confirmation or exclusion of colorectal cancer.
more...
more...